Rimini Street (NASDAQ:RMNI) & Portage Biotech (NASDAQ:ALP) Critical Review

Portage Biotech (NASDAQ:ALP) and Rimini Street (NASDAQ:RMNI) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Insider and Institutional Ownership

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 73.8% of Rimini Street shares are held by institutional investors. 42.0% of Rimini Street shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Portage Biotech has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.

Profitability

This table compares Portage Biotech and Rimini Street’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Rimini Street	1.69%	-53.91%	3.24%

Analyst Ratings

This is a summary of current ratings and recommmendations for Portage Biotech and Rimini Street, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1	2	0	0	1.67
Rimini Street	0	3	3	0	2.50

Portage Biotech currently has a consensus price target of $12.50, suggesting a potential upside of 210.95%. Rimini Street has a consensus price target of $6.33, suggesting a potential upside of 54.85%. Given Portage Biotech’s higher probable upside, equities research analysts plainly believe Portage Biotech is more favorable than Rimini Street.

Earnings & Valuation

This table compares Portage Biotech and Rimini Street”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	$100,000.00	62.31	-$38.63 million	($409.00)	-0.01
Rimini Street	$421.54 million	0.91	$37.10 million	$0.08	51.12

Rimini Street has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.

Summary

Rimini Street beats Portage Biotech on 10 of the 13 factors compared between the two stocks.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.

About Rimini Street

Rimini Street, Inc. provides enterprise software products, services, and support. The company engages in the provision of support services for Oracle and SAP enterprise software products. It also provides Rimini ONE, an outsourcing option that offers a set of unified and integrated services to run, manage, support, customize, configure, connect, protect, monitor, and optimize its clients’ application, database, and technology enterprise software; Rimini Support, a mission-critical support for Oracle, SAP, proprietary and open-source database, and technology software; Rimini Manage, a suite of managed services for application and database software; Rimini Protect, a suite of personalized software security services and solutions; and Rimini Connect, a suite of managed interoperability solutions for browsers, operating systems, and email systems. In addition, the company offers Rimini Watch, a suite of observability solutions that include monitoring and system health check solutions; Rimini Consult, a suite of professional services for clients’ enterprise software customization, configuration, implementation, integration, interoperability, migration, staff augmentation, and other project needs; and Rimini Custom, a program that expands support and related services to a broader portfolio of enterprise software. The company serves Fortune 500 companies and Fortune Global 100 companies across various industries. It sells its solutions primarily through direct sales organizations in North America, Latin America, Europe, Africa, the Middle East, Asia, and the Asia-Pacific. The company was incorporated in 2005 and is headquartered in Las Vegas, Nevada.